Formulation and Characterization of Macitantan Nanoparticles for the Treatment of Pulmonary Hypertension

Nanomedicine is an emerging field with great opportunities to improve the treatment of diseases which are currently not curable. Pulmonary arterial hypertension (PAH) is one of these diseases treatable by inhalation of medicines that provide novel depots for drugs with short pharmacological half - lives to improve the quality of life for patients. In this study, positively charged nanoparticles based on chitosan were developed and synthesized to enhance penetration capability of Macitentan in order to improve the treatment to cure pulmonary arterial hypertension (PAH). This study focuses on the design and characterization of drug delivery systems with the potential to improve the treatment options for hypertonic conditions (like PAH).